Investigational drug · Phase 2
RAPA-201 Rapamycin Resistant T Cells
Also called: RAPA-201 cells
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Malignant Melanoma, Malignant Melanoma With Metastasis, Malignant Melanoma Stage IIIc.
Phase 2Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "RAPA-201 Rapamycin Resistant T Cells"
First trial start
2021
Aug 1, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RAPA-201 Rapamycin Resistant T Cells", any sponsor or status.
Conditions studied
As listed on its trial records.
- Malignant Melanoma
- Malignant Melanoma With Metastasis
- Malignant Melanoma Stage IIIc
- Malignant Melanoma Stage IV
- Solid Tumor
- Small Cell and Non-small Cell Lung Cancer
- Head and Neck Cancer
- Squamous Cell Carcinoma of Oral Cavity
- Squamous Cell Carcinoma of Larynx
- Squamous Cell Carcinoma of Nasopharynx
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "RAPA-201 Rapamycin Resistant T Cells" as an intervention, largest first.
- Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 MelanomaNot yet recruiting
Rapa Therapeutics LLCIndustry
NCT06708455 · 65 participants (planned) · Start Mar 1, 2027 · Primary completion Mar 1, 2029
Drug: RAPA-201 Rapamycin Resistant T Cells; Chemotherapy Prior to RAPA-201 Therapy · For: Malignant Melanoma With Metastasis; Malignant Melanoma; Malignant Melanoma Stage IIIc and 1 more
Sites: Hackensack, New Jersey
- RAPA-201 Therapy of Solid TumorsRecruiting
Rapa Therapeutics LLCIndustry
NCT05144698 · 37 participants (planned) · Start Aug 1, 2021 · Primary completion Jan 1, 2026
Drug: RAPA-201 Rapamycin Resistant T Cells; Chemotherapy Prior to RAPA-201 Therapy and 1 more · For: Solid Tumor; Small Cell and Non-small Cell Lung Cancer; Head and Neck Cancer and 6 more
Sites: Hackensack, New Jersey
Rapa Therapeutics LLCIndustry
NCT04176380 · 15 participants · Start Dec 2, 2020 · Primary completion Jan 30, 2023
Drug: RAPA-201 Autologous T cells · For: Relapsed, Refractory Multiple Myeloma
Sites: Milwaukee, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Malignant Melanoma
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- L19TNFL19IL2, OnfekafuspPhase 310 trials
Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III
- DNA VaccinePhase 22 trials
NEC Bio B.V · Triple Negative Breast Cancer, Malignant Melanoma, Melanoma (Skin)
- TCC1727Phase 22 trials
Beijing Tide Pharmaceutical Co., Ltd · Patients with Advanced Solid Tumors, Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)
- AMT-253Phase 21 trial
Multitude Therapeutics Inc. · Malignant Melanoma, Advanced Solid Tumors
- GM103Phase 21 trial
GeneMedicine Co., Ltd. · Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.